Novartis Vaccines announced on Monday that John Porter will be the new medical affairs director for North Europe.
Previously, Porter was the United Kingdom Medical Team Lead at Pfizer UK, where he supported therapeutic programs including vaccination.
"We are delighted to welcome Dr. Porter at this exciting time for the division as we prepare for the implementation of routine Bexsero vaccination in the U.K.," Mark Collinson, head of U.K., Ireland and Nordic countries at Novartis Vaccines, said. "His wealth of experience in the field of vaccination makes him the ideal candidate for this position and we look forward to welcoming him to the team."
Porter joins Novartis Vaccines following a recent recommendation by the Joint Committee on Vaccination and Immunisation for Meningitis B vaccine Bexsero to be included in the National Immunisation Programme. Porter will be involved in the implementation of Bexsero in the program.
"After nearly 20 years in development, Bexsero will now be made available to those who need it most," Porter said. "I look forward to working with the team here at Novartis Vaccines to ensure the swift introduction of Bexsero across the U.K., preventing further unnecessary death and disability from Meningitis B."
Porter holds a medical degree from the University of Newcastle upon Tyne Medical School and has more than 12 years of clinical experience, primarily in pediatrics. He received an honors degree in physiological sciences from Oxford University and a Ph.D. in medicine from the University of Birmingham.